ArticleScientific reports2026
Novel eugenol/limonene nanoplatform as a new remedy against bacterial lung infections.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- New Insights into the Pharmacological Effects and Potential Health Benefits of Volatile Phenylpropenes.Molecules (Basel, Switzerland) · 2026Review
- Eugenol nanoemulsion protects chickens against S. Typhimurium infection by improving cecal barrier function and alleviating oxidative stress and inflammation.Poultry science · 2026Article
- Formulation, physicochemical characterization, and antimicrobial evaluation of drug-loaded essential oil microemulsions against Methicillin-resistantFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A combinational approach to antimicrobial design emerges from a nanoemulsified nanoplatform from the union of two Egyptian essential oils-orange peel and clove-whose distinct chemistries were revealed by GC-MS. Orange EO is dominated by D-limonene (63.25%), with supporting alkyl-benzenes (22.92%) and β-myrcene (1.41%), while clove EO centers on Eugenol (36.20%), Caryophyllene (19.30%), Eugenol acetate (18.71%), along with alkyl-benzenes (11.86%) and humulene (2.41%). The chemical consonance between Eugenol and Limonene hints at a cooperative assembly: their lipophilic profiles enable the formation of nanoemulsified nanoparticles from their emulsion blend, potentially amplifying bioavailability and multi-target action. Biologically, Eugenol/Limonene demonstrates tangible antimicrobial activity. In a direct DHFR inhibition assay, the nanoformulation inhibits DHFR with an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.